(Q34178661)

31 July 2017

title

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties (English)

1 reference

31 July 2017

1 reference

Liu BL

1

1 reference

31 July 2017

Robinson M

2

1 reference

31 July 2017

Han ZQ

3

1 reference

31 July 2017

Branston RH

4

1 reference

31 July 2017

English C

5

1 reference

31 July 2017

Reay P

6

1 reference

31 July 2017

McGrath Y

7

1 reference

31 July 2017

Thomas SK

8

1 reference

31 July 2017

Thornton M

9

1 reference

31 July 2017

Bullock P

10

1 reference

31 July 2017

Love CA

11

1 reference

31 July 2017

Coffin RS

12

1 reference

31 July 2017

language of work or name

1 reference

1 February 2003

1 reference

31 July 2017

1 reference

31 July 2017

volume

10

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

292-303

1 reference

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Oncolytic biotherapy: a novel therapeutic plafform

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Cytolytic viruses as potential anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Adenovirus-mediated p53 gene therapy for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of her

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Herpes simplex virus turns off the TAP to evade host immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Biological basis for virulence of three strains of herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

A gamma34.5 mutant of herpes simplex 1 causes severe inflammation in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

Functional and molecular analyses of the avirulent wild-type herpes simplex virus type 1 strain KOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

7 January 2021

inferred from DOI database lookup

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

7 January 2021

inferred from DOI database lookup

Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301885

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.GT.3301885

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iuzvgjvazbhqjnbajmuit7gopy

30 July 2022

mapped directly with Wikidata item

Dimensions Publication ID

1014089334

0 references

Fatcat ID

release_iuzvgjvazbhqjnbajmuit7gopy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iuzvgjvazbhqjnbajmuit7gopy

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/iuzvgjvazbhqjnbajmuit7gopy

1 reference

30 July 2022